Thiadiazolidinediones as GSK-3 inhibitors

摘要

The present invention relates to new thiadiazolidinediones of formula (I), or any pharmaceutically acceptable salt, solvate or prodrug thereof, and its use in the treatment of a disease in which glycogen synthase kinase 3 (GSK-3) is involved, particularly neurodegenerative diseases, inflammatory and autoimmune diseases and cardiovascular disorders. Additionally, there is provided a process for preparing such compounds, as well as pharmaceutical compositions comprising them.

主权项

1. A compound of Formula (I): wherein: Ra is an unsubstituted ethyl, or a methyl group or an ethyl group substituted with hydroxyl, heterocyclyl or C(O)OR′, wherein R′ is an alkyl group which is a linear hydrocarbon chain radical consisting of 1 to 6 carbon atoms; Rb is —(CHR1)n—(Z)m-aryl, wherein n is 1, m is 1 or 2, and R1 is —CO(O)R″, wherein R″ is an alkyl group; Z is —C(R2)(R3)—, wherein R2 and R3 are independently selected from hydrogen and alkyl; or any pharmaceutically acceptable salt, solvate or prodrug thereof.